0 Bewertungen
ID

12574

Beschreibung

Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT01804101

Link

https://clinicaltrials.gov/show/NCT01804101

Stichworte

Versionen (1)
  1. 02/12/2015 02/12/2015 -
Hochgeladen am

2 de dezembro de 2015

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0
Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Zurück zu Modell Kommentaren
Itemgroup Kommentare für :

Item Kommentare für :

  • Neueste
  • Älteste
  • Beliebt
  • Neueste
    • Neueste
    • Älteste
    • Beliebt

    Keine Kommentare

    Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

    Eligibility Acute Biphenotypic Leukemia NCT01804101

    Englisch

    Eligibility Acute Biphenotypic Leukemia NCT01804101

    1 Formulare  
    Inclusion Criteria
    Beschreibung

    Inclusion Criteria

    Alias
    UMLS CUI
    C1512693
    Diagnosis of untreated high-risk myelodysplastic syndrome (>= 10% blasts) or aml
    Beschreibung

    other than acute promyelocytic leukemia (apl) with t(15;17)(q22;q12) or variants according to the 2008 world health organization (who) classification; patients with biphenotypic aml are eligible; outside diagnostic material is acceptable as long as peripheral blood and/or bone marrow slides are reviewed at the study institution and cytogenetic/molecular information is available

    Datentyp

    boolean

    Alias
    UMLS CUI [1]
    C3463824
    UMLS CUI [2]
    C0026998
    prior hydroxyurea for aml is permitted but should be discontinued prior to start of cpx-351 treatment
    Beschreibung

    prior hydroxyurea for aml

    Datentyp

    boolean

    Alias
    UMLS CUI [1]
    C0020402
    UMLS CUI [2]
    C0521104
    UMLS CUI [3]
    C1706472
    azacitidine, decitabine, lenalidomide, and growth factors are permitted for low-risk mds (< 10% blasts); all treatments for mds should be discontinued prior to start of cpx-351 treatment
    Beschreibung

    discontinue treatment for myelodysplastic syndrome

    Datentyp

    boolean

    Alias
    UMLS CUI [1]
    C0584668
    treatment-related mortality (trm) score >= 13.1 as calculated with simplified model
    Beschreibung

    treatment-related mortality score

    Datentyp

    boolean

    Alias
    UMLS CUI [1]
    C0457450
    bilirubin < 2.0 mg/ml x upper limit of normal; this requirement reflects the excretion of cpx-351 by the liver
    Beschreibung

    Liver function

    Datentyp

    boolean

    Alias
    UMLS CUI [1]
    C0232741
    aspartate aminotransferase (ast)/alanine aminotransferase (alt) < 4.0 x upper limit of normal; this requirement reflects the excretion of cpx-351 by the liver
    Beschreibung

    Liver function

    Datentyp

    boolean

    Alias
    UMLS CUI [1]
    C0232741
    left ventricular ejection fraction (lvef) >= 40%, assessed within 28 days prior to registration, e.g. by multi gated acquisition (muga) scan or echocardiography, or other appropriate diagnostic modality
    Beschreibung

    left ventricular ejection fraction

    Datentyp

    boolean

    Alias
    UMLS CUI [1]
    C0428772
    patients with symptoms/signs of hyperleukocytosis or white blood cell count (wbc) > 100,000/ul can be treated with leukapheresis prior to enrollment
    Beschreibung

    hyperleukocytosis or white blood cell count (wbc) > 100,000/ul can be treated with leukapheresis prior to enrollment

    Datentyp

    boolean

    Alias
    UMLS CUI [1]
    C3805210
    UMLS CUI [2]
    C0023416
    provide signed written informed consent
    Beschreibung

    informed consent

    Datentyp

    boolean

    Alias
    UMLS CUI [1]
    C0021430
    Exclusion Criteria
    Beschreibung

    Exclusion Criteria

    Alias
    UMLS CUI
    C0680251
    refractory/relapsing blast crisis of chronic myelogenous leukemia (cml)
    Beschreibung

    refractory/relapsing blast crisis of chronic myelogenous leukemia (cml)

    Datentyp

    boolean

    Alias
    UMLS CUI [1]
    C2861579
    UMLS CUI [2]
    C0205269
    concomitant illness associated with a likely survival of < 1 year
    Beschreibung

    Comorbidity with a likely survival of < 1 year

    Datentyp

    boolean

    Alias
    UMLS CUI [1]
    C0009488
    UMLS CUI [2]
    C2919552
    active systemic fungal, bacterial, viral, or other infection, unless under treatment with anti-microbials and controlled/stable, as defined as being afebrile and hemodynamically stable for 24-48 hours
    Beschreibung

    infection, unless under treatment

    Datentyp

    boolean

    Alias
    UMLS CUI [1]
    C0009450
    UMLS CUI [2]
    C0087111
    Zum Seitenanfang zurückkehren

    Ähnliche Modelle

    Eligibility Acute Biphenotypic Leukemia NCT01804101

    1 Formulare
    Name
    Typ
    Description | Question | Decode (Coded Value)
    Datentyp
    Alias
    Item Group
    C1512693 (UMLS CUI)
    untreated high-risk myelodysplastic syndrome or aml
    Item
    Diagnosis of untreated high-risk myelodysplastic syndrome (>= 10% blasts) or aml
    boolean
    C3463824 (UMLS CUI [1])
    C0026998 (UMLS CUI [2])
    prior hydroxyurea for aml
    Item
    prior hydroxyurea for aml is permitted but should be discontinued prior to start of cpx-351 treatment
    boolean
    C0020402 (UMLS CUI [1])
    C0521104 (UMLS CUI [2])
    C1706472 (UMLS CUI [3])
    discontinue treatment for myelodysplastic syndrome
    Item
    azacitidine, decitabine, lenalidomide, and growth factors are permitted for low-risk mds (< 10% blasts); all treatments for mds should be discontinued prior to start of cpx-351 treatment
    boolean
    C0584668 (UMLS CUI [1])
    treatment-related mortality score
    Item
    treatment-related mortality (trm) score >= 13.1 as calculated with simplified model
    boolean
    C0457450 (UMLS CUI [1])
    Liver function
    Item
    bilirubin < 2.0 mg/ml x upper limit of normal; this requirement reflects the excretion of cpx-351 by the liver
    boolean
    C0232741 (UMLS CUI [1])
    Liver function
    Item
    aspartate aminotransferase (ast)/alanine aminotransferase (alt) < 4.0 x upper limit of normal; this requirement reflects the excretion of cpx-351 by the liver
    boolean
    C0232741 (UMLS CUI [1])
    left ventricular ejection fraction
    Item
    left ventricular ejection fraction (lvef) >= 40%, assessed within 28 days prior to registration, e.g. by multi gated acquisition (muga) scan or echocardiography, or other appropriate diagnostic modality
    boolean
    C0428772 (UMLS CUI [1])
    hyperleukocytosis or white blood cell count (wbc) > 100,000/ul can be treated with leukapheresis prior to enrollment
    Item
    patients with symptoms/signs of hyperleukocytosis or white blood cell count (wbc) > 100,000/ul can be treated with leukapheresis prior to enrollment
    boolean
    C3805210 (UMLS CUI [1])
    C0023416 (UMLS CUI [2])
    informed consent
    Item
    provide signed written informed consent
    boolean
    C0021430 (UMLS CUI [1])
    Item Group
    C0680251 (UMLS CUI)
    refractory/relapsing blast crisis of chronic myelogenous leukemia (cml)
    Item
    refractory/relapsing blast crisis of chronic myelogenous leukemia (cml)
    boolean
    C2861579 (UMLS CUI [1])
    C0205269 (UMLS CUI [2])
    Comorbidity with a likely survival of < 1 year
    Item
    concomitant illness associated with a likely survival of < 1 year
    boolean
    C0009488 (UMLS CUI [1])
    C2919552 (UMLS CUI [2])
    infection, unless under treatment
    Item
    active systemic fungal, bacterial, viral, or other infection, unless under treatment with anti-microbials and controlled/stable, as defined as being afebrile and hemodynamically stable for 24-48 hours
    boolean
    C0009450 (UMLS CUI [1])
    C0087111 (UMLS CUI [2])
    Zum Seitenanfang zurückkehren 

    Hilfe

    Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

    Zum Video